https://scholars.lib.ntu.edu.tw/handle/123456789/551077
標題: | Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection | 作者: | TAI-CHUNG TSENG CHUN-JEN LIU TUNG-HUNG SU Yang W.-T CHI-LING CHEN HUNG-CHIH YANG Kuo S.F.-T CHEN-HUA LIU PEI-JER CHEN DING-SHINN CHEN JIA-HORNG KAO |
公開日期: | 2018 | 出版社: | Blackwell Publishing Ltd | 卷: | 47 | 期: | 11 | 起(迄)頁: | 1480-1489 | 來源出版物: | Alimentary Pharmacology and Therapeutics | 摘要: | Background: Fibrosis-4 index (FIB-4) is a surrogate marker for hepatic fibrosis in hepatitis B virus (HBV) carriers. Aim: To investigate whether FIB-4 index stratifies the risks of adverse liver events. Methods: A total of 2075 treatment-na?ve, noncirrhotic the patients with chronic HBV infection were included. Most of them (82.1%) were HBeAg-negative patients and their baseline FIB-4 levels were explored to stratify the risks of cirrhosis, cirrhosis-related complications and liver-related mortality. Results: During a mean follow-up period of 15.47?years, we found a higher baseline FIB-4 index was associated with increased incidence rates of cirrhosis in addition to the common host and viral factors. Patients with FIB-4 >1.29, compared to those with FIB-4 <1.29, were associated with increased risks of cirrhosis, cirrhosis-related complications and liver-related mortality with the hazard ratio (95% confidence interval) of 6.19 (4.76-8.05), 6.88, (3.68-12.86) and 7.79, (4.54-13.37) respectively. Within the first 3?years of follow-up, FIB-4 remained stable and its kinetics were consistently associated with the develoopment of adverse liver events. Furthermore, FIB-4 index of 1.29 was able to stratify all the risks of adverse liver events even in HBeAg-negative patients with a low risk of disease progression (HBV DNA <2000?IU/mL, HBsAg <1000?IU/mL and ALT <40?U/L). Only 1 patient with FIB-4 index <1.29 developed cirrhosis but not other events within 15?years of follow-up. Conclusions: In noncirrhotic patients with chronic HBV infection, a higher FIB-4 index was associated with increased risks of adverse liver events. FIB-4 index <1.29 is useful for the prediction of the lowest risks of disease progression. ? 2018 John Wiley & Sons Ltd |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044613817&doi=10.1111%2fapt.14619&partnerID=40&md5=aca8bbaf935bc65f25c27c2bc47a26c0 https://scholars.lib.ntu.edu.tw/handle/123456789/551077 |
ISSN: | 0269-2813 | DOI: | 10.1111/apt.14619 | SDG/關鍵字: | alanine aminotransferase; aspartate aminotransferase; hepatitis B surface antigen; biological marker; hepatitis B surface antigen; adult; age distribution; alanine aminotransferase blood level; antigen detection; Article; aspartate aminotransferase blood level; chronic hepatitis B; cohort analysis; controlled study; disease marker; disease severity; disease surveillance; DNA determination; female; fibrosis 4 index; follow up; genotype; human; incidence; liver cirrhosis; liver function test; major clinical study; male; mortality; prediction; priority journal; protein blood level; receiver operating characteristic; risk assessment; blood; chronic hepatitis B; disease exacerbation; Hepatitis B virus; liver cirrhosis; middle aged; mortality; predictive value; risk factor; Adult; Biomarkers; Disease Progression; Female; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Mortality; Predictive Value of Tests; Risk Factors |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。